Global Gastroesophageal Reflux Disease (GERD) Therapeutics Market Report 2021 - ResearchAndMarkets.com

DUBLIN--(BUSINESS WIRE)--The "Gastroesophageal Reflux Disease (GERD) Therapeutics - Global Market Trajectory & Analytics" report has been added to ResearchAndMarkets.com's offering.

Global Gastroesophageal Reflux Disease (GERD) Therapeutics Market to Reach $4.3 Billion by 2027

Amid the COVID-19 crisis, the global market for Gastroesophageal Reflux Disease (GERD) Therapeutics estimated at US$ 4.9 Billion in the year 2020, is projected to reach a revised size of US$ 4.3 Billion by 2027, growing at a CAGR of -1.8% over the analysis period 2020-2027.

Antacids, one of the segments analyzed in the report, is projected to record a -2.4% CAGR and reach US$ 1.7 Billion by the end of the analysis period. After an early analysis of the business implications of the pandemic and its induced economic crisis, growth in the H2 Receptor Blockers segment is readjusted to a revised -1.9% CAGR for the next 7-year period.

The U.S. Market is Estimated at $1.3 Billion, While China is Forecast to Grow at -3.9% CAGR

The Gastroesophageal Reflux Disease (GERD) Therapeutics market in the U.S. is estimated at US$ 1.3 Billion in the year 2020. China, the world`s second largest economy, is forecast to reach a projected market size of US$ 609 Million by the year 2027 trailing a CAGR of -3.9% over the analysis period 2020 to 2027. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at -0.4% and -1.9% respectively over the 2020-2027 period. Within Europe, Germany is forecast to grow at approximately -1% CAGR.

Proton Pump Inhibitors Segment to Record -1.3% CAGR

In the global Proton Pump Inhibitors segment, USA, Canada, Japan, China and Europe will drive the -1.1% CAGR estimated for this segment. These regional markets accounting for a combined market size of US$ 1.3 Billion in the year 2020 will reach a projected size of US$ 1.2 Billion by the close of the analysis period.

China will remain among the fastest growing in this cluster of regional markets. Led by countries such as Australia, India, and South Korea, the market in Asia-Pacific is forecast to reach US$ 469.5 Million by the year 2027, while Latin America will expand at a -1.6% CAGR through the analysis period.

Key Topics Covered:

I. METHODOLOGY

II. EXECUTIVE SUMMARY

1. MARKET OVERVIEW

• Influencer Market Insights
• World Market Trajectories
• Impact of Covid-19 and a Looming Global Recession
• Global Competitor Market Shares
• Gastroesophageal Reflux Disease (GERD) Therapeutics Competitor Market Share Scenario Worldwide (in %): 2020E
• Global Competitor Market Shares by Segment

2. FOCUS ON SELECT PLAYERS (Total 42 Featured):

• Abbott
• AstraZeneca PLC
• Daewoong Pharmaceutical Co., Ltd
• Eisai Co., Ltd.
• GlaxoSmithKline PLC
• Ironwood Pharmaceuticals, Inc.
• Johnson & Johnson Services, Inc.
• Novartis AG
• Pfizer, Inc.
• RaQualia Pharma, Inc.
• Reckitt Benckiser Group PLC
• SFJ Pharmaceuticals Group
• SRS Pharmaceuticals Pvt., Ltd
• Takeda Pharmaceutical Co., Ltd.

3. MARKET TRENDS & DRIVERS

4. GLOBAL MARKET PERSPECTIVE

III. MARKET ANALYSIS

• UNITED STATES
• Market Facts & Figures
• Market Analytics
• CANADA
• JAPAN
• CHINA
• EUROPE
• Market Facts & Figures
• Market Analytics
• FRANCE
• GERMANY
• ITALY
• UNITED KINGDOM
• SPAIN
• RUSSIA
• REST OF EUROPE
• ASIA-PACIFIC
• AUSTRALIA
• INDIA
• SOUTH KOREA
• REST OF ASIA-PACIFIC
• LATIN AMERICA
• ARGENTINA
• BRAZIL
• MEXICO
• REST OF LATIN AMERICA
• MIDDLE EAST
• IRAN
• ISRAEL
• SAUDI ARABIA
• UNITED ARAB EMIRATES
• REST OF MIDDLE EAST
• AFRICA

IV. COMPETITION

• Total Companies Profiled: 42

For more information about this report visit https://www.researchandmarkets.com/r/3f6j9m

ResearchAndMarkets.com
Laura Wood, Senior Press Manager
press@researchandmarkets.com

For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900